Look, when we unpack this latest print from $Novo Nordisk AS(NVO.US), the takeaway is pretty stark: we are looking at a structural inflection point. The absolute monopoly premium they’ve enjoyed in the GLP-1 space is officially in the rearview mirror, and the market is violently repricing this name from a 'hyper-growth tech stock' back into a 'traditional big pharma' multiple.

Here’s the core issue. While they managed a 10% top-line beat for the full year of 2025, that completely masks the exhaustion we are seeing under the hood. The massive red flag here is management’s guidance for 2026—projecting a 5% revenue decline. That completely shatters Wall Street's consensus of perpetual, double-digit growth. It's the primary catalyst behind the massive double-digit selloff we saw post-earnings.

And if you look at the margins, they are bleeding pricing power. Gross margins slipped from nearly 85% in 2024 down to 81% in Q4. U.S. sales barely eked out a 2% gain. What this tells us is that any volume growth they are getting right now is coming at the heavy expense of price cuts. The moat is cracking.

They are getting squeezed from two sides. On one flank, you have $Eli Lilly(LLY.US). Now that Lilly has largely resolved the supply bottlenecks for Zepbound, they are going on the offensive, bringing serious pressure on both efficacy and market share. On the other flank, you have the proliferation of compounding pharmacies in the U.S. that have essentially obliterated Wegovy's price floor, capping their ability to penetrate the broader, out-of-pocket market. We are transitioning from a capacity-constrained blue ocean into a red ocean price war.

@Bridge Buzz SG